Navigation Links
Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
Date:12/5/2007

EMERYVILLE, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) (NTI(R)) today announced that Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") presented interim results for XERECEPT(R) at the Annual Meeting for the Society of Neuro-Oncology.

Paul Freiman, President and Chief Executive Officer of NTI, stated, "We are pleased with our continuing involvement in the development of XERECEPT and the prospects for this drug, which is so urgently needed."

On December 4, 2007, Celtic Pharma, which acquired the rights and assets related to XERECEPT from NTI in November 2005, issued the following press release:

"New York, London and Bermuda, December 4, 2007 - Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") today reported interim study results for XERECEPT(R) (human corticotropin-releasing factor (hCRF)), which were presented at the 12th Annual Meeting of the Society for Neuro-Oncology ("SNO"), and provided an update on the XERECEPT(R) clinical development program.

"In a poster presentation at the SNO annual meeting, which took place in Dallas, Texas on November 15-18, 2007, Celtic Pharma disclosed interim results of an on-going, open-label extension trial, which is evaluating the long-term safety and efficacy of XERECEPT(R) as a new potential treatment for Peritumoral Brain Edema ("PBE"), or tumor-related brain swelling. The data presented at SNO demonstrated that 20 of the first 32 patients enrolled received XERECEPT(R) daily for at least 20 weeks. XERECEPT(R) was well- tolerated. Nine of the 20 patients discontinued dexamethasone altogether, and steroid side effects were resolved or improved in the majority of patients who received a reduced dexamet
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Corporation (NASDAQ: CYTR ), a biopharmaceutical research and ... for the three months ended June 30, 2015, and ... milestones for its clinical development programs. "The ... CytRx. Enrollment in our ongoing pivotal global Phase 3 ... continues on track to be completed in the first ...
(Date:8/3/2015)... 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) ... Quarter 2015 Investor Conference Call and webcast at 4:30 p.m., ... call will cover an update on Merrimack,s progress as ... A press release detailing the information to be discussed ... Monday, August 10. Investors and the general public are ...
(Date:8/3/2015)... Aug. 3, 2015  Celsion Corporation (NASDAQ: ... host a conference call to discuss its second ... on its development programs for ThermoDox®, its proprietary ... acquired technology platforms, TheraPlas™ and TheraSilence™, in immunotherapy ... Monday, August 10, 2015. To participate in the ...
Breaking Medicine Technology:CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Celsion Corporation to Hold Second Quarter 2015 Financial Results Conference Call on Monday, August 10, 2015 2
... 29, 2011 Robbins & Myers, Inc. ... sale of its Romaco businesses to a group of ... private equity investment firm.  Total consideration was approximately euro ... of cash and euro 4 million of assumed liabilities ...
... SILVER SPRING, Md., April 29, 2011 Don,t let expired ... dispose of them properly to prevent them from harming others. ... part in the second annual National Prescription Drug Take-Back Day, ... View a slideshow and read a Consumer Update ...
Cached Medicine Technology:
(Date:8/4/2015)... ... August 04, 2015 , ... Oriental ... and crafts, toys, novelties, and school supplies, has developed engaging and affordable teacher ... exclusive collection includes student rewards, classroom decorations, crafts and educational resources featuring ...
(Date:8/4/2015)... ... August 04, 2015 , ... It is National Psoriasis Awareness Month, and we ... symptoms such as dry, itching, burning or soreness of skin that may crack or ... they find what’s right for them. Then, what is effective may stop working, so ...
(Date:8/4/2015)... York, NY (PRWEB) , ... August 04, 2015 , ... ... all but universal, though the desire for invasive surgery to achieve this ideal is ... offer the results people crave without the high cost or lengthy recovery time, according ...
(Date:8/4/2015)... ... ... Nathan’s Famous was recently featured on NewsWatch as part of ... an impact in their industry. Andrew Tropeano, the host of NewsWatch and business expert, ... now offers a 50% Reduced Fat All-Beef Frank variety and is celebrating summer ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... developing the most recent episode which spotlights treating depression. Depression affects millions of ... disease, "In America" wants to inform and enlighten viewers with the latest segment ...
Breaking Medicine News(10 mins):Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 3Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 3Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 2Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 3
... in the middle ear, a condition called otitis media with ... antihistamines and decongestants, a new review of studies has found.// ... alleviating symptoms or avoiding complications of OME and expose children ... ,"This review finds no benefit for any of the short- ...
... the hepatitis C virus during the first part of 1990, ... hospital which was not sufficiently screened for safety. ,Following ... test for Hepatitis C came out into the open. ... screening for any liver condition. ,The Labor Party's ...
... exploits are titillated by personality traits, contemplates a new ... The idea that personality types may increase the susceptibility ... ,Researchers at the University of Chicago have ... for cancer as compared to the rats that portrayed ...
... researchers, stress among youth associated with parental separation and ... at the John Moores University in Liverpool have found ... parents in recognizing the physical and emotional changes in ... and mental health. ,According to them, there ...
... exhaust of diesel trucks constitute a major contributor to ... children// in the South Bronx, according to the results ... University’s School of Medicine and Robert F. Wagner Graduate ... the study, asthma symptoms, particularly wheezing, doubled among elementary ...
... have found the brain’s natural antioxidant defense mechanism to ... ,According to the researchers at the Dana-Farber Cancer ... harmful effects of toxic ‘free radicals’ that are the ... with aging and certain degenerative brain diseases, heart attack, ...
Cached Medicine News:Health News:Allergy Drugs More Harmful Than Helpful for Chronic Ear Inflammation 2Health News:Allergy Drugs More Harmful Than Helpful for Chronic Ear Inflammation 3Health News:Stress brings about early onset of puberty 2Health News:Asthma Symptoms Linked to Soot from Diesel Trucks in So. Bronx 2Health News:Asthma Symptoms Linked to Soot from Diesel Trucks in So. Bronx 3